BioCryst Pharmaceuticals’ (BCRX) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) in a research report sent to investors on Tuesday morning,Benzinga reports. They currently have a $30.00 price objective on the biotechnology company’s stock. HC Wainwright also issued estimates for BioCryst Pharmaceuticals’ Q2 2025 earnings at $0.10 EPS, Q3 2025 earnings at $0.13 EPS, Q4 2025 earnings at $0.13 EPS, FY2025 earnings at $0.35 EPS, FY2026 earnings at $0.56 EPS, FY2027 earnings at $0.88 EPS, FY2028 earnings at $1.29 EPS and FY2029 earnings at $2.14 EPS.

A number of other research firms have also recently issued reports on BCRX. Royal Bank of Canada reissued an “outperform” rating and set a $11.00 price objective on shares of BioCryst Pharmaceuticals in a research report on Friday, April 11th. Wedbush began coverage on BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an “outperform” rating and a $15.00 price target for the company. Cantor Fitzgerald started coverage on BioCryst Pharmaceuticals in a research report on Tuesday, April 29th. They set an “overweight” rating and a $20.00 target price for the company. Evercore ISI lifted their price target on shares of BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an “outperform” rating in a research report on Monday, January 13th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $18.00 target price on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, BioCryst Pharmaceuticals currently has an average rating of “Buy” and a consensus target price of $16.56.

BioCryst Pharmaceuticals Price Performance

BioCryst Pharmaceuticals stock opened at $9.92 on Tuesday. BioCryst Pharmaceuticals has a fifty-two week low of $5.06 and a fifty-two week high of $11.11. The firm’s 50 day simple moving average is $7.84 and its 200-day simple moving average is $7.88. The company has a market cap of $2.08 billion, a P/E ratio of -16.26 and a beta of 1.08.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. During the same period in the prior year, the firm earned $0.28 EPS. The firm’s quarterly revenue was up 40.8% on a year-over-year basis. On average, analysts expect that BioCryst Pharmaceuticals will post -0.36 EPS for the current fiscal year.

Hedge Funds Weigh In On BioCryst Pharmaceuticals

A number of hedge funds have recently modified their holdings of the stock. Vanguard Group Inc. lifted its holdings in shares of BioCryst Pharmaceuticals by 7.8% during the fourth quarter. Vanguard Group Inc. now owns 21,890,422 shares of the biotechnology company’s stock valued at $164,616,000 after acquiring an additional 1,583,826 shares during the period. Teacher Retirement System of Texas boosted its position in BioCryst Pharmaceuticals by 25.1% in the 4th quarter. Teacher Retirement System of Texas now owns 58,291 shares of the biotechnology company’s stock valued at $438,000 after buying an additional 11,711 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in shares of BioCryst Pharmaceuticals by 4.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company’s stock valued at $14,890,000 after acquiring an additional 91,998 shares during the period. Raymond James Financial Inc. acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter worth about $80,000. Finally, Choreo LLC bought a new stake in shares of BioCryst Pharmaceuticals during the fourth quarter worth approximately $106,000. 85.88% of the stock is owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.